SCHEMBL302980

SCHEMBL302980

CN(C)S(=O)(=O)N(Cc1ccc(F)cc1)c1ccc(C(=O)N2CCOC(c3ccccc3)C2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
ATM Q13315 1/20 0.48
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
LMNA P02545 4/20 0.44
HPGD P15428 3/20 0.43
ALDH1A1 P00352 2/20 0.42
NAMPT P43490 1/20 0.42
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
HTT P42858 2/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PDE2A O00408 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
USP30 Q70CQ3 1/20 0.40
KCNA5 P22460 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303273 0.94 HPGD (0.48) NPC1RAB9AATMKMT2AMEN1
SCHEMBL20394957 0.84 NAMPT (0.40) NPC1RAB9AATMKMT2AMEN1
SCHEMBL302312 0.84 USP30 (0.39) RAB9AKMT2AMEN1LMNAHPGD
SCHEMBL301981 0.78 LMNA (0.47) KMT2AMEN1LMNAHPGDALDH1A1
SCHEMBL302896 0.77 LMNA (0.46) KMT2ALMNAHPGDALDH1A1GAA
SCHEMBL303569 0.77 LMNA (0.46) KMT2AMEN1LMNAHPGDALDH1A1
SCHEMBL3275571 0.76 NPC1 (0.52) NPC1RAB9AATMKMT2AMEN1
SCHEMBL3275575 0.76 NPC1 (0.52) NPC1RAB9AATMKMT2AMEN1
SCHEMBL3378993 0.75 LMNA (0.48) KMT2AMEN1LMNAHPGDALDH1A1
SCHEMBL12017331 0.73 GAA (0.51) KMT2AMEN1LMNAHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
JP-2012500834-A 2012-01-12 JP claimed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 NPC1 474/4885RAB9A 2125/4885ATM 4027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.